Antilymphangiogenic therapy to promote transplant survival and to reduce cancer metastasis: What can we learn from the eye?

Seminars in Cell and Developmental Biology

Volumn 38, Issue , 2015, Pages 117-130

  Hos, Deniz ^a   Schlereth, Simona L ^a   Bock, Felix ^a   Heindl, Ludwig M ^a   Cursiefen, Claus ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Antilymphangiogenic therapy; Cornea; Lymphangiogenesis; Ocular malignancies; Transplantation; Tumor associated lymphangiogenesis

Indexed keywords

ANTIANGIOGENIC THERAPY; CORNEA TRANSPLANTATION; DRY EYE; EYE ALLERGY; GRAFT REJECTION; GRAFT SURVIVAL; HERPES SIMPLEX KERATITIS; HUMAN; LYMPH VESSEL; LYMPHANGIOGENESIS; METASTASIS; NONHUMAN; REVIEW; TUMOR MICROENVIRONMENT; ANIMAL; DRUG EFFECTS; EYE; EYE DISEASES; EYE TUMOR; NEOPLASM METASTASIS; PATHOLOGY;

ANIMALS; CORNEAL TRANSPLANTATION; EYE; EYE DISEASES; EYE NEOPLASMS; HUMANS; LYMPHANGIOGENESIS; NEOPLASM METASTASIS;

EID: 84928102372     PISSN: 10849521     EISSN: 10963634     Source Type: Journal    
DOI: 10.1016/j.semcdb.2014.11.003     Document Type: Review

References (141)

1. Alitalo K., Tammela T., Petrova T.V. Lymphangiogenesis in development and human disease. Nature 2005, 438:946-953.
2. Tammela T., Alitalo K. Lymphangiogenesis: molecular mechanisms and future promise. Cell 2010, 140:460-476.
3. Cursiefen C., Schlotzer-Schrehardt U., Kuchle M., Sorokin L., Breiteneder-Geleff S., Alitalo K., et al. Lymphatic vessels in vascularized human corneas: immunohistochemical investigation using LYVE-1 and podoplanin. Invest Ophthalmol Vis Sci 2002, 43:2127-2135.
4. Cursiefen C. Immune privilege and angiogenic privilege of the cornea. Chem Immunol Allergy 2007, 92:50-57.
5. Cursiefen C., Chen L., Dana M.R., Streilein J.W. Corneal lymphangiogenesis: evidence, mechanisms, and implications for corneal transplant immunology. Cornea 2003, 22:273-281.
6. Steven P., Bock F., Huttmann G., Cursiefen C. Intravital two-photon microscopy of immune cell dynamics in corneal lymphatic vessels. PLoS ONE 2011, 6:e26253.
7. Albuquerque R.J., Hayashi T., Cho W.G., Kleinman M.E., Dridi S., Takeda A., et al. Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. Nat Med 2009, 15:1023-1030.
8. Chang L.K., Garcia-Cardena G., Farnebo F., Fannon M., Chen E.J., Butterfield C., et al. Dose-dependent response of FGF-2 for lymphangiogenesis. Proc Natl Acad Sci U S A 2004, 101:11658-11663.
9. Cursiefen C., Maruyama K., Bock F., Saban D., Sadrai Z., Lawler J., et al. Thrombospondin 1 inhibits inflammatory lymphangiogenesis by CD36 ligation on monocytes. J Exp Med 2011, 208:1083-1092.
10. Cursiefen C., Chen L., Borges L.P., Jackson D., Cao J., Radziejewski C., et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest 2004, 113:1040-1050.
11. Bos F.L., Caunt M., Peterson-Maduro J., Planas-Paz L., Kowalski J., Karpanen T., et al. CCBE1 is essential for mammalian lymphatic vascular development and enhances the lymphangiogenic effect of vascular endothelial growth factor-C in vivo. Circ Res 2011, 109:486-491.
12. Niederkorn J.Y. The immune privilege of corneal allografts. Transplantation 1999, 67:1503-1508.
13. Streilein J.W., Yamada J., Dana M.R., Ksander B.R. Anterior chamber-associated immune deviation, ocular immune privilege, and orthotopic corneal allografts. Transplant Proc 1999, 31:1472-1475.
14. Niederkorn J.Y. High-risk corneal allografts and why they lose their immune privilege. Curr Opin Allergy Clin Immunol 2010, 10:493-497.
15. Dana M.R., Streilein J.W. Loss and restoration of immune privilege in eyes with corneal neovascularization. Invest Ophthalmol Vis Sci 1996, 37:2485-2494.
16. Bachmann B., Taylor R.S., Cursiefen C. Corneal neovascularization as a risk factor for graft failure and rejection after keratoplasty: an evidence-based meta-analysis. Ophthalmology 2010, 117. 1300-5.e7.
17. Dietrich T., Bock F., Yuen D., Hos D., Bachmann B.O., Zahn G., et al. Cutting edge: lymphatic vessels, not blood vessels, primarily mediate immune rejections after transplantation. J Immunol 2010, 184:535-539.
18. Kerjaschki D., Regele H.M., Moosberger I., Nagy-Bojarski K., Watschinger B., Soleiman A., et al. Lymphatic neoangiogenesis in human kidney transplants is associated with immunologically active lymphocytic infiltrates. J Am Soc Nephrol 2004, 15:603-612.
19. Kerjaschki D., Huttary N., Raab I., Regele H., Bojarski-Nagy K., Bartel G., et al. Lymphatic endothelial progenitor cells contribute to de novo lymphangiogenesis in human renal transplants. Nat Med 2006, 12:230-234.
20. Nykanen A.I., Sandelin H., Krebs R., Keranen M.A., Tuuminen R., Karpanen T., et al. Targeting lymphatic vessel activation and CCL21 production by vascular endothelial growth factor receptor-3 inhibition has novel immunomodulatory and antiarteriosclerotic effects in cardiac allografts. Circulation 2010, 121:1413-1422.
21. Heindl L.M., Hofmann T.N., Knorr H.L., Rummelt C., Schrodl F., Schlotzer-Schrehardt U., et al. Intraocular lymphangiogenesis in malignant melanomas of the ciliary body with extraocular extension. Invest Ophthalmol Vis Sci 2009, 50:1988-1995.
22. Heindl L.M., Hofmann-Rummelt C., Adler W., Bosch J.J., Holbach L.M., Naumann G.O., et al. Tumor-associated lymphangiogenesis in the development of conjunctival melanoma. Invest Ophthalmol Vis Sci 2011, 52:7074-7083.
23. Heindl L.M., Hofmann-Rummelt C., Adler W., Holbach L.M., Naumann G.O., Kruse F.E., et al. Tumor-associated lymphangiogenesis in the development of conjunctival squamous cell carcinoma. Ophthalmology 2010, 117:649-658.
24. Zimmermann P., Dietrich T., Bock F., Horn F.K., Hofmann-Rummelt C., Kruse F.E., et al. Tumour-associated lymphangiogenesis in conjunctival malignant melanoma. Br J Ophthalmol 2009, 93:1529-1534.
25. Heindl L.M., Hofmann T.N., Adler W., Knorr H.L., Holbach L.M., Naumann G.O., et al. Intraocular tumor-associated lymphangiogenesis a novel prognostic factor for ciliary body melanomas with extraocular extension?. Ophthalmology 2010, 117:334-342.
26. Heindl L.M., Hofmann T.N., Schrodl F., Holbach L.M., Kruse F.E., Cursiefen C. Intraocular lymphatics in ciliary body melanomas with extraocular extension: functional for lymphatic spread?. Arch Ophthalmol 2010, 128:1001-1008.
27. Heindl L.M., Hofmann-Rummelt C., Adler W., Bosch J.J., Holbach L.M., Naumann G.O., et al. Prognostic significance of tumor-associated lymphangiogenesis in malignant melanomas of the conjunctiva. Ophthalmology 2011, 118:2351-2360.
28. Hos D., Bachmann B., Bock F., Onderka J., Cursiefen C. Age-related changes in murine limbal lymphatic vessels and corneal lymphangiogenesis. Exp Eye Res 2008, 87:427-432.
29. Cursiefen C., Maruyama K., Jackson D.G., Streilein J.W., Kruse F.E. Time course of angiogenesis and lymphangiogenesis after brief corneal inflammation. Cornea 2006, 25:443-447.
30. Bock F., Maruyama K., Regenfuss B., Hos D., Steven P., Heindl L.M., et al. Novel anti(lymph)angiogenic treatment strategies for corneal and ocular surface diseases. Prog Retin Eye Res 2013, 34:89-124.
31. Schroedl F., Brehmer A., Neuhuber W.L., Kruse F.E., May C.A., Cursiefen C. The normal human choroid is endowed with a significant number of lymphatic vessel endothelial hyaluronate receptor 1 (LYVE-1)-positive macrophages. Invest Ophthalmol Vis Sci 2008, 49:5222-5229.
32. Schlereth S.L., Neuser B., Caramoy A., Grajewski R.S., Koch K.R., Schrodl F., et al. Enrichment of lymphatic vessel endothelial hyaluronan receptor 1 (LYVE1)-positive macrophages around blood vessels in the normal human sclera. Invest Ophthalmol Vis Sci 2014, 55:865-872.
33. Schlereth S.L., Neuser B., Herwig M.C., Muller A.M., Koch K.R., Reitsamer H.A., et al. Absence of lymphatic vessels in the developing human sclera. Exp Eye Res 2014, 125C:203-209.
34. Wessel J.M., Hofmann-Rummelt C., Kruse F.E., Cursiefen C., Heindl L.M. Invasion of lymphatic vessels into the eye after open globe injuries. Invest Ophthalmol Vis Sci 2012, 53:3717-3725.
35. Cursiefen C., Rummelt C., Junemann A., Vorwerk C., Neuhuber W., Kruse F.E., et al. Absence of blood and lymphatic vessels in the developing human cornea. Cornea 2006, 25:722-726.
36. Ambati B.K., Nozaki M., Singh N., Takeda A., Jani P.D., Suthar T., et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature 2006, 443:993-997.
37. Singh N., Tiem M., Watkins R., Cho Y.K., Wang Y., Olsen T., et al. Soluble vascular endothelial growth factor receptor-3 is essential for corneal alymphaticity. Blood 2013, 121:4242-4249.
38. Cursiefen C., Chen L., Saint-Geniez M., Hamrah P., Jin Y., Rashid S., et al. Nonvascular VEGF receptor 3 expression by corneal epithelium maintains avascularity and vision. Proc Natl Acad Sci U S A 2006, 103:11405-11410.
39. Armstrong L.C., Bornstein P. Thrombospondins 1 and 2 function as inhibitors of angiogenesis. Matrix Biol: J Int Soc Matrix Biol 2003, 22:63-71.
40. Cursiefen C., Masli S., Ng T.F., Dana M.R., Bornstein P., Lawler J., et al. Roles of thrombospondin-1 and -2 in regulating corneal and iris angiogenesis. Invest Ophthalmol Vis Sci 2004, 45:1117-1124.
41. Makino Y., Cao R., Svensson K., Bertilsson G., Asman M., Tanaka H., et al. Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 2001, 414:550-554.
42. Regenfuss B., Onderka J., Bock F., Hos D., Maruyama K., Cursiefen C. Genetic heterogeneity of lymphangiogenesis in different mouse strains. Am J Pathol 2010, 177:501-510.
43. Bock F., Onderka J., Hos D., Horn F., Martus P., Cursiefen C. Improved semiautomatic method for morphometry of angiogenesis and lymphangiogenesis in corneal flatmounts. Exp Eye Res 2008, 87:462-470.
44. Blacher S., Detry B., Bruyere F., Foidart J.M., Noel A. Additional parameters for the morphometry of angiogenesis and lymphangiogenesis in corneal flat mounts. Exp Eye Res 2009, 89:274-276.
45. D'Amato R.J., Loughnan M.S., Flynn E., Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994, 91:4082-4085.
46. Schulz M.M., Reisen F., Zgraggen S., Fischer S., Yuen D., Kang G.J., et al. Phenotype-based high-content chemical library screening identifies statins as inhibitors of in vivo lymphangiogenesis. Proc Natl Acad Sci U S A 2012, 109:E2665-E2674.
47. Bock F., Onderka J., Dietrich T., Bachmann B., Kruse F.E., Paschke M., et al. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci 2007, 48:2545-2552.
48. Hos D., Bock F., Dietrich T., Onderka J., Kruse F.E., Thierauch K.H., et al. Inflammatory corneal (lymph)angiogenesis is blocked by VEGFR-tyrosine kinase inhibitor ZK 261991, resulting in improved graft survival after corneal transplantation. Invest Ophthalmol Vis Sci 2008, 49:1836-1842.
49. Gross J., Azizkhan R.G., Biswas C., Bruns R.R., Hsieh D.S., Folkman J. Inhibition of tumor growth, vascularization, and collagenolysis in the rabbit cornea by medroxyprogesterone. Proc Natl Acad Sci U S A 1981, 78:1176-1180.
50. Kenyon B.M., Voest E.E., Chen C.C., Flynn E., Folkman J., D'Amato R.J. A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci 1996, 37:1625-1632.
51. Chauhan S.K., Jin Y., Goyal S., Lee H.S., Fuchsluger T.A., Lee H.K., et al. A novel pro-lymphangiogenic function for Th17/IL-17. Blood 2011, 118:4630-4634.
52. Lee H., Schlereth S.L., Park E.Y., Emami-Naeini P., Chauhan S.K., Dana R. A novel pro-angiogenic function for interferon-gamma-secreting natural killer cells. Invest Ophthalmol Vis Sci 2014, 55:2885-2892.
53. Sano Y., Ksander B.R., Streilein J.W. Fate of orthotopic corneal allografts in eyes that cannot support anterior chamber-associated immune deviation induction. Invest Ophthalmol Vis Sci 1995, 36:2176-2185.
54. Hos D., Saban D.R., Bock F., Regenfuss B., Onderka J., Masli S., et al. Suppression of inflammatory corneal lymphangiogenesis by application of topical corticosteroids. Arch Ophthalmol 2011, 129:445-452.
55. Ecoiffier T., Yuen D., Chen L. Differential distribution of blood and lymphatic vessels in the murine cornea. Invest Ophthalmol Vis Sci 2010, 51:2436-2440.
56. Hos D., Cursiefen C. Lymphatic vessels in the development of tissue and organ rejection. Adv Anat Embryol Cell Biol 2014, 214:119-141.
57. Hos D., Regenfuss B., Bock F., Onderka J., Cursiefen C. Blockade of insulin receptor substrate-1 inhibits corneal lymphangiogenesis. Invest Ophthalmol Vis Sci 2011, 52:5778-5785.
58. Cursiefen C., Bock F., Horn F.K., Kruse F.E., Seitz B., Borderie V., et al. GS-101 antisense oligonucleotide eye drops inhibit corneal neovascularization: interim results of a randomized phase II trial. Ophthalmology 2009, 116:1630-1637.
59. Cursiefen C., Viaud E., Bock F., Geudelin B., Ferry A., Kadlecova P., et al. Aganirsen antisense oligonucleotide eye drops inhibit keratitis-induced corneal neovascularization and reduce need for transplantation: the I-CAN study. Ophthalmology 2014.
60. Bock F., Matthaei M., Reinhard T., Bohringer D., Christoph J., Ganslandt T., et al. High-dose subconjunctival cyclosporine A implants do not affect corneal neovascularization after high-risk keratoplasty. Ophthalmology 2014, 121:1677-1682.
61. Cursiefen C., Kuchle M., Naumann G.O. Angiogenesis in corneal diseases: histopathologic evaluation of 254 human corneal buttons with neovascularization. Cornea 1998, 17:611-613.
62. Goyal S., Chauhan S.K., El Annan J., Nallasamy N., Zhang Q., Dana R. Evidence of corneal lymphangiogenesis in dry eye disease: a potential link to adaptive immunity?. Arch Ophthalmol 2010, 128:819-824.
63. Wuest T.R., Carr D.J. VEGF-A expression by HSV-1-infected cells drives corneal lymphangiogenesis. J Exp Med 2010, 207:101-115.
64. Stern M.E., Schaumburg C.S., Pflugfelder S.C. Dry eye as a mucosal autoimmune disease. Int Rev Immunol 2013, 32:19-41.
65. Barabino S., Chen Y., Chauhan S., Dana R. Ocular surface immunity: homeostatic mechanisms and their disruption in dry eye disease. Prog Retin Eye Res 2012, 31:271-285.
66. Stevenson W., Chauhan S.K., Dana R. Dry eye disease: an immune-mediated ocular surface disorder. Arch Ophthalmol 2012, 130:90-100.
67. De Paiva C.S., Chotikavanich S., Pangelinan S.B., Pitcher J.D., Fang B., Zheng X., et al. IL-17 disrupts corneal barrier following desiccating stress. Mucosal Immunol 2009, 2:243-253.
68. Niederkorn J.Y., Stern M.E., Pflugfelder S.C., De Paiva C.S., Corrales R.M., Gao J., et al. Desiccating stress induces T cell-mediated Sjogren's Syndrome-like lacrimal keratoconjunctivitis. J Immunol 2006, 176:3950-3957.
69. Schaumburg C.S., Siemasko K.F., De Paiva C.S., Wheeler L.A., Niederkorn J.Y., Pflugfelder S.C., et al. Ocular surface APCs are necessary for autoreactive T cell-mediated experimental autoimmune lacrimal keratoconjunctivitis. J Immunol 2011, 187:3653-3662.
70. Goyal S., Chauhan S.K., Dana R. Blockade of prolymphangiogenic vascular endothelial growth factor C in dry eye disease. Arch Ophthalmol 2012, 130:84-89.
71. Zgraggen S., Ochsenbein A.M., Detmar M. An important role of blood and lymphatic vessels in inflammation and allergy. J Allergy 2013, 2013:672381.
72. Saban D.R. The chemokine receptor CCR7 expressed by dendritic cells: a key player in corneal and ocular surface inflammation. Ocular Surf. 2014, 12:87-99.
73. Schlereth S., Lee H.S., Khandelwal P., Saban D.R. Blocking CCR7 at the ocular surface impairs the pathogenic contribution of dendritic cells in allergic conjunctivitis. Am J Pathol 2012, 180:2351-2360.
74. Maruyama K., Ii M., Cursiefen C., Jackson D.G., Keino H., Tomita M., et al. Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. J Clin Invest 2005, 115:2363-2372.
75. Dana M.R. Angiogenesis and lymphangiogenesis-implications for corneal immunity. Semin Ophthalmol 2006, 21:19-22.
76. Patel S.P., Dana R. Corneal lymphangiogenesis: implications in immunity. Semin Ophthalmol 2009, 24:135-138.
77. Yamagami S., Dana M.R. The critical role of lymph nodes in corneal alloimmunization and graft rejection. Invest Ophthalmol Vis Sci 2001, 42:1293-1298.
78. Yamagami S., Dana M.R., Tsuru T. Draining lymph nodes play an essential role in alloimmunity generated in response to high-risk corneal transplantation. Cornea 2002, 21:405-409.
79. Bock F., Onderka J., Dietrich T., Bachmann B., Pytowski B., Cursiefen C. Blockade of VEGFR3-signalling specifically inhibits lymphangiogenesis in inflammatory corneal neovascularisation. Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2008, 246:115-119.
80. Dietrich T., Onderka J., Bock F., Kruse F.E., Vossmeyer D., Stragies R., et al. Inhibition of inflammatory lymphangiogenesis by integrin alpha5 blockade. Am J Pathol 2007, 171:361-372.
81. Bock F., Konig Y., Kruse F., Baier M., Cursiefen C. Bevacizumab (Avastin) eye drops inhibit corneal neovascularization. Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2008, 246:281-284.
82. Ferrari G., Dastjerdi M.H., Okanobo A., Cheng S.F., Amparo F., Nallasamy N., et al. Topical ranibizumab as a treatment of corneal neovascularization. Cornea 2013, 32:992-997.
83. Chang J.H., Gabison E.E., Kato T., Azar D.T. Corneal neovascularization. Curr Opin Ophthalmol 2001, 12:242-249.
84. Koenig Y., Bock F., Horn F., Kruse F., Straub K., Cursiefen C. Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization. Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2009, 247:1375-1382.
85. Detry B., Blacher S., Erpicum C., Paupert J., Maertens L., Maillard C., et al. Sunitinib inhibits inflammatory corneal lymphangiogenesis. Invest Ophthalmol Vis Sci 2013, 54:3082-3093.
86. Bucher F., Parthasarathy A., Bergua A., Onderka J., Regenfuss B., Cursiefen C., et al. Topical ranibizumab inhibits inflammatory corneal hem- and lymphangiogenesis. Acta Ophthalmol (Copenh) 2012, 92:143-148.
87. Cursiefen C., Wenkel H., Martus P., Langenbucher A., Nguyen N.X., Seitz B., et al. Impact of short-term versus long-term topical steroids on corneal neovascularization after non-high-risk keratoplasty. Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2001, 239:514-521.
88. Dastjerdi M.H., Sadrai Z., Saban D.R., Zhang Q., Dana R. Corneal penetration of topical and subconjunctival bevacizumab. Invest Ophthalmol Vis Sci 2011, 52:8718-8723.
89. Dastjerdi M.H., Al-Arfaj K.M., Nallasamy N., Hamrah P., Jurkunas U.V., Pineda R., et al. Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study. Arch Ophthalmol 2009, 127:381-389.
90. Cheng S.F., Dastjerdi M.H., Ferrari G., Okanobo A., Bower K.S., Ryan D.S., et al. Short-term topical bevacizumab in the treatment of stable corneal neovascularization. Am J Ophthalmol 2012, 154. 940-8.e1.
91. Andrieu-Soler C., Berdugo M., Doat M., Courtois Y., BenEzra D., Behar-Cohen F. Downregulation of IRS-1 expression causes inhibition of corneal angiogenesis. Invest Ophthalmol Vis Sci 2005, 46:4072-4078.
92. Cloutier F., Lawrence M., Goody R., Lamoureux S., Al-Mahmood S., Colin S., et al. Antiangiogenic activity of aganirsen in nonhuman primate and rodent models of retinal neovascular disease after topical administration. Invest Ophthalmol Vis Sci 2012, 53:1195-1203.
93. Bachmann B.O., Luetjen-Drecoll E., Bock F., Wiegand S.J., Hos D., Dana R., et al. Transient postoperative vascular endothelial growth factor (VEGF)-neutralisation improves graft survival in corneas with partly regressed inflammatory neovascularisation. Br J Ophthalmol 2009, 93:1075-1080.
94. Koenig Y., Bock F., Kruse F.E., Stock K., Cursiefen C. Angioregressive pretreatment of mature corneal blood vessels before keratoplasty: fine-needle vessel coagulation combined with anti-VEGFs. Cornea 2012, 31:887-892.
95. Brooks B.J., Ambati B.K., Marcus D.M., Ratanasit A. Photodynamic therapy for corneal neovascularisation and lipid degeneration. Br J Ophthalmol 2004, 88:840.
96. Morisada T., Oike Y., Yamada Y., Urano T., Akao M., Kubota Y., et al. Angiopoietin-1 promotes LYVE-1-positive lymphatic vessel formation. Blood 2005, 105:4649-4656.
97. Song S.H., Kim K.L., Lee K.A., Suh W. Tie1 regulates the Tie2 agonistic role of angiopoietin-2 in human lymphatic endothelial cells. Biochem Biophys Res Commun 2012, 419:281-286.
98. Holzer M.P., Solomon K.D., Vroman D.T., Sandoval H.P., Margaron P., Kasper T.J., et al. Photodynamic therapy with verteporfin in a rabbit model of corneal neovascularization. Invest Ophthalmol Vis Sci 2003, 44:2954-2958.
99. Yoon K.C., Ahn K.Y., Lee S.E., Kim K.K., Im S.K., Oh H.J., et al. Experimental inhibition of corneal neovascularization by photodynamic therapy with verteporfin. Curr Eye Res 2006, 31:215-224.
100. Tammela T., Saaristo A., Holopainen T., Yla-Herttuala S., Andersson L.C., Virolainen S., et al. Photodynamic ablation of lymphatic vessels and intralymphatic cancer cells prevents metastasis. Sci Transl Med 2011, 3. 69ra11.
101. Bucher F., Bi Y., Gehlsen U., Hos D., Cursiefen C., Bock F. Regression of mature lymphatic vessels in the cornea by photodynamic therapy. Br J Ophthalmol 2014, 98:391-395.
102. Gausas R.E., Gonnering R.S., Lemke B.N., Dortzbach R.K., Sherman D.D. Identification of human orbital lymphatics. Ophthal Plast Reconstr Surg 1999, 15:252-259.
103. Dithmar S., Diaz C.E., Grossniklaus H.E. Intraocular melanoma spread to regional lymph nodes: report of two cases. Retina 2000, 20:76-79.
104. Padera T.P., Kadambi A., di Tomaso E., Carreira C.M., Brown E.B., Boucher Y., et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 2002, 296:1883-1886.
105. Achen M.G., Jeltsch M., Kukk E., Makinen T., Vitali A., Wilks A.F., et al. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A 1998, 95:548-553.
106. Cohen V.M., Tsimpida M., Hungerford J.L., Jan H., Cerio R., Moir G. Prospective study of sentinel lymph node biopsy for conjunctival melanoma. Br J Ophthalmol 2013, 97:1525-1529.
107. Pfeiffer M.L., Savar A., Esmaeli B. Sentinel lymph node biopsy for eyelid and conjunctival tumors: what have we learned in the past decade?. Ophthal Plast Reconstr Surg 2013, 29:57-62.
108. Fidler I.J. Cancer metastasis. Br Med Bull 1991, 47:157-177.
109. Schlereth S.L., Refaian N., Iden S., Cursiefen C., Heindl L.M. Impact of the prolymphangiogenic crosstalk in the tumor microenvironment on lymphatic cancer metastasis. BioMed Res Int 2014, 2014:639058.
110. Ungefroren H., Sebens S., Seidl D., Lehnert H., Hass R. Interaction of tumor cells with the microenvironment. Cell Commun Signal 2011, 9:18.
111. Barleon B., Sozzani S., Zhou D., Weich H.A., Mantovani A., Marme D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996, 87:3336-3343.
112. Lin E.Y., Nguyen A.V., Russell R.G., Pollard J.W. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 2001, 193:727-740.
113. Mantovani A., Sozzani S., Locati M., Allavena P., Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002, 23:549-555.
114. Duong T., Koopman P., Francois M. Tumor lymphangiogenesis as a potential therapeutic target. J Oncol 2012, 2012:204946.
115. Schoppmann S.F., Birner P., Stockl J., Kalt R., Ullrich R., Caucig C., et al. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol 2002, 161:947-956.
116. Bronkhorst I.H., Ly L.V., Jordanova E.S., Vrolijk J., Versluis M., Luyten G.P., et al. Detection of M2-macrophages in uveal melanoma and relation with survival. Invest Ophthalmol Vis Sci 2011, 52:643-650.
117. Ly L.V., Baghat A., Versluis M., Jordanova E.S., Luyten G.P., van Rooijen N., et al. In aged mice, outgrowth of intraocular melanoma depends on proangiogenic M2-type macrophages. J Immunol 2010, 185:3481-3488.
118. Makitie T., Summanen P., Tarkkanen A., Kivela T. Tumor-infiltrating macrophages (CD68(+) cells) and prognosis in malignant uveal melanoma. Invest Ophthalmol Vis Sci 2001, 42:1414-1421.
119. Bronkhorst I.H., Vu T.H., Jordanova E.S., Luyten G.P., Burg S.H., Jager M.J. Different subsets of tumor-infiltrating lymphocytes correlate with macrophage influx and monosomy 3 in uveal melanoma. Invest Ophthalmol Vis Sci 2012, 53:5370-5378.
120. Quezada S.A., Peggs K.S., Simpson T.R., Allison J.P. Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunol Rev 2011, 241:104-118.
121. Cao R., Bjorndahl M.A., Religa P., Clasper S., Garvin S., Galter D., et al. PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell 2004, 6:333-345.
122. Chang L., Kaipainen A., Folkman J. Lymphangiogenesis new mechanisms. Ann NY Acad Sci 2002, 979:111-119.
123. Gale N.W., Thurston G., Hackett S.F., Renard R., Wang Q., McClain J., et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1. Dev Cell 2002, 3:411-423.
124. Kubo H., Cao R., Brakenhielm E., Makinen T., Cao Y., Alitalo K. Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea. Proc Natl Acad Sci U S A 2002, 99:8868-8873.
125. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
126. Dadras S.S., Paul T., Bertoncini J., Brown L.F., Muzikansky A., Jackson D.G., et al. Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol 2003, 162:1951-1960.
127. Cao Y., Opinion: emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis. Nat Rev Cancer 2005, 5:735-743.
128. Streit M., Detmar M. Angiogenesis, lymphangiogenesis, and melanoma metastasis. Oncogene 2003, 22:3172-3179.
129. Darash-Yahana M., Pikarsky E., Abramovitch R., Zeira E., Pal B., Karplus R., et al. Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. FASEB J: Off Publ Fed Am Soc Exp Biol 2004, 18:1240-1242.
130. Muller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56.
131. Arya M., Patel H.R., McGurk C., Tatoud R., Klocker H., Masters J., et al. The importance of the CXCL12-CXCR4 chemokine ligand-receptor interaction in prostate cancer metastasis. J Exp Ther Oncol 2004, 4:291-303.
132. Achen M.G., Stacker S.A. Molecular control of lymphatic metastasis. Ann NY Acad Sci 2008, 1131:225-234.
133. He Y., Kozaki K., Karpanen T., Koshikawa K., Yla-Herttuala S., Takahashi T., et al. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst 2002, 94:819-825.
134. Zhang D., Li B., Shi J., Zhao L., Zhang X., Wang C., et al. Suppression of tumor growth and metastasis by simultaneously blocking vascular endothelial growth factor (VEGF)-A and VEGF-C with a receptor-immunoglobulin fusion protein. Cancer Res 2010, 70:2495-2503.
135. Thiele W., Sleeman J.P. Tumor-induced lymphangiogenesis: a target for cancer therapy?. J Biotechnol 2006, 124:224-241.
136. Alfonso-Perez M., Lopez-Giral S., Quintana N.E., Loscertales J., Martin-Jimenez P., Munoz C. Anti-CCR7 monoclonal antibodies as a novel tool for the treatment of chronic lymphocyte leukemia. J Leukoc Biol 2006, 79:1157-1165.
137. Somovilla-Crespo B., Alfonso-Perez M., Cuesta-Mateos C., Carballo-de Dios C., Beltran A.E., Terron F., et al. Anti-CCR7 therapy exerts a potent anti-tumor activity in a xenograft model of human mantle cell lymphoma. J Hematol Oncol 2013, 6:89.
138. Dashkevich A., Heilmann C., Kayser G., Germann M., Beyersdorf F., Passlick B., et al. Lymph angiogenesis after lung transplantation and relation to acute organ rejection in humans. Ann Thoracic Surg 2010, 90:406-411.
139. Ishii E., Shimizu A., Kuwahara N., Arai T., Kataoka M., Wakamatsu K., et al. Lymphangiogenesis associated with acute cellular rejection in rat liver transplantation. Transplant Proc 2010, 42:4282-4285.
140. Palin N.K., Savikko J., Koskinen P.K. Sirolimus inhibits lymphangiogenesis in rat renal allografts, a novel mechanism to prevent chronic kidney allograft injury. Transpl Int: Off J Eur Soc Organ Transplant 2013, 26:195-205.
141. Yin N., Zhang N., Xu J., Shi Q., Ding Y., Bromberg J.S. Targeting lymphangiogenesis after islet transplantation prolongs islet allograft survival. Transplantation 2011, 92:25-30.